At OSR Holdings, our model allows the hub to provide centralized overarching expertise and resources, while spokes focus on individual unique core competencies. This gives us flexibility to scale operations, promote collaboration, and diversify risk. Operationally we aim to reduce costs, enhance efficiency and elevate the probability of success. Uniquely at OSR Holdings, we leverage a global network across the US, Europe and Korea to identify and develop a wide range of healthcare solutions with the potential to have a real impact in patients lives.

Hub-and-Spoke Healthcare

At OSR Holdings, our model allows the hub to provide centralized overarching expertise and resources, while spokes focus on individual unique core competencies. This gives us flexibility to scale operations, promote collaboration, and diversify risk. Operationally we aim to reduce costs, enhance efficiency and elevate the probability of success. Uniquely at OSR Holdings, we leverage a global network across the US, Europe and Korea to identify and develop a wide range of healthcare solutions with the potential to have a real impact in patients lives.

At OSR Holdings, we partner with biopharmaceuticals that have innovative, proprietary R&D platforms, rather than single assets. By taking 100% ownership in our spoke companies, we maintain full operational and strategic control. We constantly evaluate M&A opportunities that advance innovative healthcare, whether through addressing unmet patient needs or lowering patient costs and burden. We are focused on portfolio expansion across the U.S., Europe, and Korea. Our technologies currently include:

Immuno-Oncology: Development of oral T-cell activation therapies targeting tumor vasculature and associated structures.
Regenerative Biologics: Design-Augmented (DA) biologics aimed at treating age-related and degenerative diseases.
Medical Device Technologies: Distribution of neurovascular intervention systems and, pending due diligence, a move into noninvasive glucose monitoring devices.

Strategic Portfolio Expansion

At OSR Holdings, we partner with biopharmaceuticals that have innovative, proprietary R&D platforms, rather than single assets. By taking 100% ownership in our spoke companies, we maintain full operational and strategic control. We constantly evaluate M&A opportunities that advance innovative healthcare, whether through addressing unmet patient needs or lowering patient costs and burden. We are focused on portfolio expansion across the U.S., Europe, and Korea. Our technologies currently include:

Immuno-Oncology: Development of oral T-cell activation therapies targeting tumor vasculature and associated structures.
Regenerative Biologics: Design-Augmented (DA) biologics aimed at treating age-related and degenerative diseases.
Medical Device Technologies: Distribution of neurovascular intervention systems and, pending due diligence, a move into noninvasive glucose monitoring devices.